Table 2.

Meta-analyses showing oncological outcomes

Ref.	Trials (n)	Patients (n)	OS lap vs open	DFS lap vs open	LR lap vs open	LN harvested lap vs open (n)	CRM positivity lap vs open
Huang et al[25]	6	1033	HR = 0.76, P = 0.11, 4 trials (3 yr)	HR = 1.13, P = 0.64, 3 trials (3 yr)	RR = 0.55, P = 0.21, 4 trials (3 yr)	P = 0.43, 5 trials	7.94% vs 5.37%, P = 0.63, 5 trials (3 yr)
Ohtani et al[26]	12	2095	N/A	OR = 1.17, P = 0.35 (5 yr)	OR = 0.93, P = 0.61 (5 yr)	P = NS	P = NS
Anderson et al[27]	24	3158	72% vs 65%, P = NS, 13 trials (3 yr)	N/A	7% vs 8%, P = NS, 16 trials (3 yr)	10 vs 11, P = 0.001 17 trials	5% vs 8%, P = NS, 10 trials (3 yr)
Aziz et al[28]	20	2071	N/A	N/A	N/A	P = NS	9.5% vs 10.8%, OR = 0.93, P = 0.38

OS: Overall survival; DFS: Disease free survival; LR: Local recurrence; LN: Lymph nodes; CRM: Circumferential margins; HR: Hazard ratio; N/A: Not applicable; NS: Non-significant; OR: Odds ratio.